JP7212138B2 - 抗ｃｄ４０抗体及びその使用 - Google Patents

抗ｃｄ４０抗体及びその使用 Download PDF

Info

Publication number
JP7212138B2
JP7212138B2 JP2021504146A JP2021504146A JP7212138B2 JP 7212138 B2 JP7212138 B2 JP 7212138B2 JP 2021504146 A JP2021504146 A JP 2021504146A JP 2021504146 A JP2021504146 A JP 2021504146A JP 7212138 B2 JP7212138 B2 JP 7212138B2
Authority
JP
Japan
Prior art keywords
seq
nos
amino acid
antibody
acid sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021504146A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500004A (ja
Inventor
ヤン，イー
ドン，チュニャン
ヤン，ファン
ル，チェンユアン
シェン，ユエレイ
ニ，ジアン
グオ，ヤンアン
チェン，ユンユン
シェ，ジンシュ
Original Assignee
ヨウキュア（ベイジン）バイオファーマ カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヨウキュア（ベイジン）バイオファーマ カンパニー リミテッド filed Critical ヨウキュア（ベイジン）バイオファーマ カンパニー リミテッド
Publication of JP2022500004A publication Critical patent/JP2022500004A/ja
Priority to JP2023003355A priority Critical patent/JP2023037000A/ja
Application granted granted Critical
Publication of JP7212138B2 publication Critical patent/JP7212138B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021504146A 2018-07-20 2018-07-20 抗ｃｄ４０抗体及びその使用 Active JP7212138B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023003355A JP2023037000A (ja) 2018-07-20 2023-01-12 抗ｃｄ４０抗体及びその使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/096494 WO2020014974A1 (en) 2018-07-20 2018-07-20 Anti-cd40 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023003355A Division JP2023037000A (ja) 2018-07-20 2023-01-12 抗ｃｄ４０抗体及びその使用

Publications (2)

Publication Number Publication Date
JP2022500004A JP2022500004A (ja) 2022-01-04
JP7212138B2 true JP7212138B2 (ja) 2023-01-24

Family

ID=69164892

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021504146A Active JP7212138B2 (ja) 2018-07-20 2018-07-20 抗ｃｄ４０抗体及びその使用
JP2023003355A Pending JP2023037000A (ja) 2018-07-20 2023-01-12 抗ｃｄ４０抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023003355A Pending JP2023037000A (ja) 2018-07-20 2023-01-12 抗ｃｄ４０抗体及びその使用

Country Status (12)

Country Link
US (3) US11142582B2 (https=)
EP (1) EP3823987A4 (https=)
JP (2) JP7212138B2 (https=)
KR (1) KR102728939B1 (https=)
CN (1) CN112566933B (https=)
AU (1) AU2018432434B2 (https=)
BR (1) BR112021001083A2 (https=)
CA (1) CA3105875A1 (https=)
IL (1) IL280281B2 (https=)
MX (2) MX2021000688A (https=)
SG (1) SG11202100510PA (https=)
WO (1) WO2020014974A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023037000A (ja) * 2018-07-20 2023-03-14 ヨウキュア（ベイジン）バイオファーマ カンパニー リミテッド 抗ｃｄ４０抗体及びその使用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4229096A4 (en) * 2020-10-14 2024-06-12 Eucure (Beijing) Biopharma Co., Ltd ANTI-PD-1/CD40 BISPECIFIC ANTIBODIES AND USES THEREOF
KR20250005109A (ko) * 2022-04-15 2025-01-09 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 항-cd40 항체 및 이의 용도
US20230404642A1 (en) * 2022-06-01 2023-12-21 Syncromune, Inc. Method for the treatment of cancer via tumor cell lysis and intratumoral administration of combinations of immunotherapeutic ingredients
CN116023495B (zh) * 2022-09-05 2023-10-03 上海百英生物科技股份有限公司 一种抗cd40纳米抗体及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012520074A (ja) 2009-03-10 2012-09-06 ベイラー リサーチ インスティテュート 抗ｃｄ４０抗体及びその使用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
JP4041535B2 (ja) 1989-08-18 2008-01-30 オックスフォード バイオメディカ（ユーケー）リミテッド 標的細胞にベクター構造体を運搬する組換レトロウィルス
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
WO2007130493A2 (en) 2006-05-03 2007-11-15 Regents Of The University Of Colorado Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
SI2531527T1 (sl) 2010-02-04 2014-07-31 F. Hoffmann-La Roche Ag Monoklonsko protitelo proti CD44 za uporabo pri zdravljenju skvamoznoceličnega karcinoma glave in vratu
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
CN113461819B (zh) 2011-04-29 2024-01-02 埃派斯进有限公司 抗-cd40抗体及其使用方法
AU2013337903B2 (en) 2012-10-30 2018-08-16 Apexigen, Inc. Anti-CD40 antibodies and methods of use
HK1252666A1 (zh) * 2015-06-29 2019-05-31 Bristol-Myers Squibb Company 针对cd40的抗体
WO2017040932A1 (en) * 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
US12297266B2 (en) 2016-04-18 2025-05-13 Celldex Therapeutics, Inc. Agonistic antibodies that bind human CD40 and uses thereof
WO2018233607A1 (en) 2017-06-19 2018-12-27 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric cd40
JP7212138B2 (ja) * 2018-07-20 2023-01-24 ヨウキュア（ベイジン）バイオファーマ カンパニー リミテッド 抗ｃｄ４０抗体及びその使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012520074A (ja) 2009-03-10 2012-09-06 ベイラー リサーチ インスティテュート 抗ｃｄ４０抗体及びその使用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023037000A (ja) * 2018-07-20 2023-03-14 ヨウキュア（ベイジン）バイオファーマ カンパニー リミテッド 抗ｃｄ４０抗体及びその使用

Also Published As

Publication number Publication date
MX2025000992A (es) 2025-03-07
IL280281B2 (en) 2025-08-01
CN112566933B (zh) 2023-07-14
IL280281A (en) 2021-03-25
AU2018432434A1 (en) 2021-01-28
US12134653B2 (en) 2024-11-05
JP2022500004A (ja) 2022-01-04
US20250034271A1 (en) 2025-01-30
US20210403588A1 (en) 2021-12-30
US11142582B2 (en) 2021-10-12
BR112021001083A2 (pt) 2021-05-11
WO2020014974A1 (en) 2020-01-23
EP3823987A1 (en) 2021-05-26
US20210155705A1 (en) 2021-05-27
IL280281B1 (en) 2025-04-01
EP3823987A4 (en) 2022-03-02
AU2018432434B2 (en) 2025-11-20
CA3105875A1 (en) 2020-01-23
MX2021000688A (es) 2021-03-25
SG11202100510PA (en) 2021-02-25
KR102728939B1 (ko) 2024-11-11
JP2023037000A (ja) 2023-03-14
KR20210033029A (ko) 2021-03-25
CN112566933A (zh) 2021-03-26

Similar Documents

Publication Publication Date Title
US11155625B2 (en) Anti-PD-1 antibodies and uses thereof
US20240352141A1 (en) Anti-ox40 antibodies and uses thereof
US12134653B2 (en) Anti-CD40 antibodies and uses thereof
WO2020253722A1 (en) Anti-cd40 antibodies and uses thereof
RU2796413C2 (ru) Антитела против cd40 и их применения
RU2788616C2 (ru) Антитела против pd-1 и их применение
HK40047604A (en) Anti-cd40 antibodies and uses thereof
HK40047604B (zh) 抗cd40抗体及其用途
HK40040324B (en) Anti-pd-1 antibodies and uses thereof
HK40040324A (zh) 抗pd-1抗体及其用途
HK40039579A (en) Anti-ox40 antibodies and uses thereof
HK40039579B (en) Anti-ox40 antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210720

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220906

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221213

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230112

R150 Certificate of patent or registration of utility model

Ref document number: 7212138

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250